Bone-marrow transplantation for acute lymphoblastic leukaemia

Area of Science:

• Hematology
• Oncology
• Transplantation Immunology

Background:

• Acute lymphoblastic leukaemia (ALL) remains a significant challenge, necessitating effective treatment strategies.
• Bone-marrow transplantation (BMT) is a potential curative option for ALL.
• Optimizing BMT protocols, including timing and patient risk stratification, is crucial for improving outcomes.

Purpose of the Study:

• To evaluate the long-term survival and relapse rates of acute lymphoblastic leukaemia (ALL) patients undergoing HLA-identical sibling bone-marrow transplantation.
• To compare outcomes based on disease remission status (first vs. second remission) and risk stratification (standard vs. high-risk).

Main Methods:

• Retrospective analysis of 106 patients with ALL in first or second remission and 98 patients with advanced disease.
• Actuarial survival and relapse rates were calculated at 4 years post-transplant.
• Comparison of outcomes between patients transplanted in first vs. second remission, and between standard-risk and high-risk groups.

Main Results:

• Four-year actuarial survival was 43% in patients transplanted in first/second remission and 15% in advanced disease patients.
• Relapse rates were 32% in first/second remission and 67% in advanced disease.
• High-risk patients transplanted in first remission showed higher survival (55%) than those in second remission (41%), with comparable relapse rates.

Conclusions:

• Long-term disease-free survival is achievable in ALL patients through bone-marrow transplantation.
• Transplantation in first remission may offer survival advantages, although further research is needed to confirm this.
• Relapse rates were similar between first and second remission transplants, highlighting the need for continued risk stratification and treatment optimization.